Collectively our findings demonstrate that the ZEB2–ephrinB2 axis is a crucial regulator of tumour invasion in glioma, whose blockade can overcome evasive resistance following anti-angiogenic treatment. Here, EFNB2 is linked to central nervous system cancer.